STC IntraDermal injection
Strict and AI assisted selection of specific allogeneic tumor cell lines provides those most representative of the targeted indication.
The scalable and unique STC Platform is an allogeneic technology which mimics and represents the cellular heterogeneity of the patient’s tumor. REPRESENTATIVITY (diversity) is ensured by cell lines selected from a data base and with in vitro tests (cold tumor, hot tumor, oncogenic drivers : TP53, BRAF, KRAS,….).
STC technology educates the immune system with the widest range of neo-antigens of interest.
Our technology prepares and trains the representative cells of interest: Firstly, through physical exposure (low radiation – heat shock) and secondly, with chemical treatment (clinical cytotoxic molecules). The ANTIGENICITY (plasticity) of our solution is ensured by more than 200 neo-antigens expressed on the cell surface. The neo-antigens are TAA (Tumor Associated Antigens) – TSA (Tumor Specific Antigens) which constitute the largest range of resistance factors.
In a very innovative way, and to ensure the IMMUNOGENICITY of our solution, a recognition tag associated with surface neo-antigens is added by haptenization. This step makes the solution, which is already representative and antigenic, visible to the patient’s immune system, and therefore very immunogenic.
Our product can be administered in combination with SOC such as chemotherapy thus not changing the clinical practice of physicians in the different treated conditions.
High capability to speed-up the generation of new candidates leveraging the same technology platform.
Very strong IP portfolio with the first patents being granted in key countries (EU5, JP, US).
Industrial design built for an efficient and scalable manufacturing process.
Dendritic cell maturation
TILs pool generation specific for resistance factors.
TILs specifically destroys primary and resistant tumor cells.